Elsevier Announces Nutraceuticals: Efficacy, Safety and Toxicity,
and Updated Edition of the Best-Selling Drug-Like Properties
14 mars 2016 04h00 HE
|
Elsevier, Inc.
CAMBRIDGE, MA--(Marketwired - March 14, 2016) -
Elsevier, a world-leading provider of scientific, technical and medical information products and services, today announced the publication of...
Hemispherx Biopharma Exploring Possible Research Programs in Zika Virus Modeled on a Prior Alferon® N Clinical Trial on Closely Related Flavivirus (West Nile)
09 févr. 2016 08h30 HE
|
AIM ImmunoTech Inc.
PHILADELPHIA, Feb. 09, 2016 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) announced today that it is beginning to consider study designs for potential tests of the activity and...
Concerned Parents Want National Dialogue on Pot and Violence
30 oct. 2015 14h10 HE
|
Parents Opposed to Pot
WASHINGTON, DC, Oct. 30, 2015 (GLOBE NEWSWIRE) -- October is Domestic Violence Awareness Month. Parents Opposed to Pot and Parents for a Healthy Colorado are calling for a national discussion on...
Hemispherx Biopharma Europe N.V./S.A. Receives Positive Opinion on Application for Orphan Designation by the European Medicines Agency for Alferon N Injection to Treat Patients With Middle East Respiratory Syndrome (MERS)
19 oct. 2015 08h30 HE
|
AIM ImmunoTech Inc.
PHILADELPHIA, Oct. 19, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the “Company” or “Hemispherx”) announces that the European subsidiary, “Hemispherx Biopharma Europe...
Hemispherx Biopharma Receives the European Patent Office Grant of New Composition of Matter Patent Covering Ampligen(R) Formulations
28 sept. 2015 08h30 HE
|
AIM ImmunoTech Inc.
PHILADELPHIA, Sept. 28, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced that it received formal notice on September 21, 2015, that the...
Hemispherx Biopharma Reports Article by Senior Authors From Italian Ministry of Health and Related Agencies Suggesting Broad Applicability of Ampligen(R) to Multiple Sclerosis
23 sept. 2015 08h30 HE
|
AIM ImmunoTech Inc.
PHILADELPHIA, Sept. 23, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced today a new peer reviewed article, with senior authors from the Italian Ministry of Health and other...
Hemispherx Biopharma Extends Its Strategic Alliance With Armada Health Care for Alferon N Injection(R)
17 août 2015 08h30 HE
|
AIM ImmunoTech Inc.
PHILADELPHIA, Aug. 17, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE:HEB) (the "Company" or "Hemispherx"), announced that as the Company works toward the re-launch of Alferon N, it has...
Hemispherx Biopharma Europe N.V./S.A. Submits Application for Orphan Medicine Designation to the EMA for Alferon N Injection(R) for Treatment of Middle East Respiratory Syndrome (MERS)
15 juil. 2015 08h30 HE
|
AIM ImmunoTech Inc.
PHILADELPHIA, July 15, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx") announces that they have submitted an application for orphan drug designation...
Hemispherx Biopharma Europe N.V./S.A.: Orphan Medicine Designation and European Medicines Agency Public Opinion Summary Published by EMA Regarding Ampligen/Rintatolimod for Ebola Virus Disease (EVD)
26 mai 2015 12h46 HE
|
AIM ImmunoTech Inc.
PHILADELPHIA, May 26, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx") announces that the European Medicines Agency (EMA) has published on May 22,...
Hemispherx Biopharma Europe N.V./S.A. Receives Orphan Medicine Designation by the European Medicines Agency for Ampligen to Treat Patients With Ebola Virus Disease (EVD)
11 mai 2015 08h30 HE
|
AIM ImmunoTech Inc.
PHILADELPHIA, May 11, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx") announces that its European subsidiary, Hemispherx Biopharma Europe N.V./S.A.,...